Chemours stock moves after recent performance in focus

Chemours (CC) has drawn fresh attention after a strong recent run, with the share price around $22.71 and sizeable gains over the past month and past 3 months prompting closer scrutiny from investors.

The recent rally, including a 29.25% 1 month share price return and 85.39% year to date share price return, contrasts with a weaker 3 year total shareholder return of a 14.69% decline. This suggests that momentum has picked up after a difficult stretch.

If Chemours has caught your eye, it can help to see what else is moving, so take a look at 8 top copper producer stocks

With Chemours trading around $22.71, sitting above its analyst price target and carrying an estimated 60% intrinsic discount, the key question is whether the recent surge leaves upside on the table or if markets already reflect expectations for future growth.

Most Popular Narrative: 39% Overvalued

Chemours last closed at $22.71, while the most followed narrative pegs fair value closer to $16.33 using an 11.18% discount rate and detailed cash flow assumptions.

Progress in resolving legacy PFAS litigation risk highlighted by the New Jersey settlement and insurance recoveries has significantly improved long-term earnings visibility and reduced potential future cash outflows, removing a major overhang and enhancing free cash flow conversion.

Want to understand why this narrative still lands on a lower fair value despite that legal progress? The answer ties together revenue, margins, and a future earnings multiple that sits well below typical industry levels.

Result: Fair Value of $16.33 (OVERVALUED)

However, you still have to weigh PFAS litigation exposure and regulatory pressure on fluorinated chemicals, which could affect cash flows and limit flexibility if outcomes worsen.

Another Take: Multiples Point to a Different Story

The narrative fair value of $16.33 relies on detailed cash flow assumptions and a discount rate. On a simple P/S basis, Chemours trades at about 0.6x, compared with 1.1x for the US Chemicals industry and a fair ratio of 1.2x. This comparison suggests the market could move closer to that level over time.

That gap suggests investors may be pricing in heavier risks or weaker future growth than peers. The key question is whether those concerns justify such a wide discount or leave room for a re rating if sentiment shifts.

Next Steps

With mixed signals on value and risk throughout this story, now is the time to check the underlying data yourself and decide where you stand by carefully weighing the 3 key rewards and 2 important warning signs.

Looking for more investment ideas?

If Chemours has raised your curiosity, now is the moment to widen your watchlist and spot opportunities you might regret missing later.

• Target dependable cash generators by scanning for companies in the 58 high quality undervalued stocks that pair sensible prices with solid fundamentals.
• Strengthen your defense by reviewing the 72 resilient stocks with low risk scores that focus on resilient balance sheets and lower risk profiles.
• Spot early standouts before the crowd by checking the screener containing 23 high quality undiscovered gems packed with under followed names that still show quality traits.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.